8 Jul 2020
Whole-genome sequencing offers the ability to reduce pediatric diagnostic odysseys which cost at least $14 billion annually in the U.S.
SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (NASDAQ: ILMN) is bringing turn-key data analysis solutions to accelerate and facilitate the adoption of whole-genome sequencing with the launch of the TruSight™ Software Suite. TruSight Software delivers ready-made infrastructure to realize the full potential of whole-genome sequencing for rare genetic diseases. This new offering enables sample-to-report analysis for genetic disease testing, giving customers an integrated solution that focuses on one of the most challenging parts of the workflow, empowering researchers to go from 5 million variants to a small handful, in a rapid, scalable way. TruSight Software will make it easier for people to benefit from the valuable insights enabled by genomic sequencing.
“The future of pediatric medicine will include whole genome sequencing for suspected genetic disorders,” said William Morice, M.D., Ph.D., President, Mayo Clinic Laboratories, and Department Chair, Laboratory Medicine and Pathology at Mayo Clinic in Rochester, MN. “Enabling laboratories and physicians with access to efficient, clinical-grade whole-genome sequencing solutions is essential.”
“This combination of products will set the standard for scalable and swift interpretation of genomic information, enabling whole-genome sequencing to become the standard of care in rare diseases,” said Ryan Taft, Vice President of Scientific Research at Illumina. “By enabling users to quickly sift through millions of variants to find an answer, we will make it easier for rare disease patients to benefit from valuable genomic insights.”
More than 250 million people are affected by rare genetic diseases globally. These conditions can be debilitating with families frequently spending upwards of five years being referred from doctor to doctor, enduring a diagnostic odyssey often fraught with misdiagnoses, inappropriate treatments and procedures, all in search for an underlying cause. These diagnostic odysseys are expensive. In the U.S. alone it is estimated that pediatric genetic diseases cost at least $14 billion every year. And, in some cases it’s a race against time, where an early diagnosis can dramatically improve patient outcomes – potentially even helping a young child live a healthier, fuller life. As one of the most comprehensive genetic tests available, whole-genome sequencing offers the potential to shorten the time and reduce the cost of identifying these genetic conditions, and the most likely to end the diagnostic odyssey.
The key to realizing the promise of precision medicine relies on accurate and specific diagnosis. Each human genome comprises more than 3 billion nucleotides of which roughly 5 million variations are unique to each individual. A slight modification of one or two of these variations can mean the difference between being healthy and having a serious genetic disease. Finding these critical few variants is currently the most challenging technical obstacle for genetic testing. TruSight Software Suite is a powerful compilation of tools and innovation thoughtfully designed to drive through the noise to find those disease-causing variants.
TruSight Software Suite, developed in collaboration with Mayo Clinic and other key opinion leaders, reduces the interpretation bottleneck from as much as weeks to as little as hours. TruSight Software Suite, when combined with Illumina's NovaSeq™ 6000 and Illumina DNA PCR-Free Prep, offers a complete whole-genome sequencing analysis workflow designed to help evaluate, visualize, curate and report on rare variants.
To learn more, click here.
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
Use of forward-looking statements
This release contains forward-looking statements that involve risks and uncertainties, including the expectation for lower costs related to the storing and managing of genomic data costs. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing and launching new products and services; (ii) our ability to deploy new products, services, and applications, and to expand the markets for our technology platforms; and (iii) the acceptance by customers of our newly launched products, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current quarter.
Jacquie Ross, CFA
Europe, Middle East and Africa Media:
Dr. Karen Birmingham
+44 7500 105665
Source: Illumina, Inc.